ClinicalTrials.gg
RecruitingNCT06994182employers_2024Updated Nov 20, 2026

Perspectives of Italian Employers Regarding the Return to Work Process of Employees Who Received a Cancer Diagnosis: a Qualitative Study

An observational study in Cancer Survivors, sponsored by Azienda USL Reggio Emilia - IRCCS. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Azienda USL Reggio Emilia - IRCCS · Observational

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.
Updated Nov 20, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
18 Years and older
Sex
All
01

Study summary

European Cancer Mission calls attention to the return to work (RTW) of cancer survivors (CSs), as one of the pivotal issues of the cancer continuum that need to be addressed through proper and prompt actions and recommendations. Employers are important stakeholders, as they can provide emotional and practical support, sustain communication during the entire process, and guarantee a gradual work reintegration. In Italy there is lack of knowledge regarding this topic. Thus, further exploration of Italian employers' perspectives on the RTW of employees with cancer should be performed to comprehend their unknown experiences.

The aim is to explore the perspectives of employers who dealt with the RTW process of employees who received a cancer diagnosis through a qualitative research design.

Read the detailed description

Data collection will be performed through individual semi-structured interviews. Each interview will last around 60 minutes, and it can be arranged in person or remotely, depending on the participant's preference. Socio-demographic data, expertise of the employer, and company-related data will be collected through a semi-structured interview.

Experiences of employers will be collected through open-ended questions using an interview guide that was written based on the one used by Tiedtke et al., 2017, by adding some questions related to the facilitators and barriers perceived by employers during the sickness absence and RTW of employee with cancer.

The open-ended questions will concern general information about the company, employers' experience after cancer disclosure and during sick leave, employers' experience to sustain the RTW process and the long-term work reintegration, and the influence of the experience on the company.

Each interview will be audio-recorded, transcribed verbatim and analyzed according to the thematic analysis method using an inductive approach with open coding.

Analysis will be iterative and involve multiple researchers to ensure inter-rater reliability of the coding procedure and the methodological rigor of the analysis.

Themes generated will be discussed with Dutch researchers from the Amsterdam University Medical Centers.

Analyses will be carried out at the end of each interview because, based on the themes that will emerge from each interview, we will understand when to stop recruiting.

02

Conditions studied

  • Cancer Survivors

Keywords

  • Cancer Survivors
  • Return to work
  • Employers
  • Qualitative Research
03

In context

Lead sponsor

Azienda USL Reggio Emilia - IRCCS is the lead sponsor of 93 studies on the registry; 24 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population consists of employers of the province of Reggio Emilia who managed the RTW process of employees with a cancer diagnosis. This population includes employers from companies with diverse characteristics (type of company and sector, and number of employees) to collect the perspectives of employers working in different settings.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. employers* of a company
  2. being directly involved in managing the RTW process of at least one employee with cancer diagnosis in the last 5 years.

    • An employer can be the specific person who represents the company where the employee was working at the time of cancer diagnosis or a person who supported the employee during the sickness absence and the RTW process (e.g., line manager, human resource manager).

Exclusion criteria

Exclusion Criteria:

  • none
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (estimated)
Patient registry
No

Groups and cohorts

  • Employers

    This cohort includes employers of active companies located in the province of Reggio Emilia. The Chamber of Commerce dell 'Emilia will provide a random list of the active company based on the type of company (profit, non-for-profit), type of sector (i.e., manufacturing, constructions), and number of employees (small, medium, large) to guarantee the representativeness of our context.

06

What researchers measure

Primary outcomes

  1. 1. Open-ended questions of a semi-structured interview to collect the employers experience of the management of the RTW process

    Themes describing how employers managed the RTW process of employees with cancer, of their feeling and thoughts, of what actions did they do, and of the relationships and communication with the other members of the company

    Time frame: 12 months

  2. Open-ended questions of a semi-structured interview to collect the employers' necessities while supporting the RTW process

    Themes describing what employers require to support employees who receive a cancer diagnosis in the RTW process

    Time frame: 12 months

  3. Open-ended questions of a semi-structured interview to collect the employers perceived barriers and facilitators while supporting the RTW process

    Themes describing the facilitators and barriers perceived by employers during the RTW process of employees who received a cancer diagnosis. For this outcome, themes will be classified using the Resource Dependence Institutional Cooperation (RDIC) model, developed by Rijk et al. and adjusted by Greidanus et al. (2018).

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Greidanus MA, de Boer AGEM, de Rijk AE, Tiedtke CM, Dierckx de Casterle B, Frings-Dresen MHW, Tamminga SJ. Perceived employer-related barriers and facilitators for work participation of cancer survivors: A systematic review of employers' and survivors' perspectives. Psychooncology. 2018 Mar;27(3):725-733. doi: 10.1002/pon.4514. Epub 2017 Sep 6. PubMed 28753741 ↗
  • Lawler M, De Lorenzo F, Lagergren P, Mennini FS, Narbutas S, Scocca G, Meunier F; European Academy of Cancer Sciences. Challenges and solutions to embed cancer survivorship research and innovation within the EU Cancer Mission. Mol Oncol. 2021 Jul;15(7):1750-1758. doi: 10.1002/1878-0261.13022. Epub 2021 Jun 15. PubMed 34053182 ↗
  • Paltrinieri S, Fugazzaro S, Bertozzi L, Bassi MC, Pellegrini M, Vicentini M, Mazzini E, Costi S. Return to work in European Cancer survivors: a systematic review. Support Care Cancer. 2018 Sep;26(9):2983-2994. doi: 10.1007/s00520-018-4270-6. Epub 2018 May 29. PubMed 29845421 ↗
  • de Rijk A, Amir Z, Cohen M, Furlan T, Godderis L, Knezevic B, Miglioretti M, Munir F, Popa AE, Sedlakova M, Torp S, Yagil D, Tamminga S, de Boer A. The challenge of return to work in workers with cancer: employer priorities despite variation in social policies related to work and health. J Cancer Surviv. 2020 Apr;14(2):188-199. doi: 10.1007/s11764-019-00829-y. Epub 2019 Nov 22. PubMed 31758518 ↗
  • Tiedtke CM, Dierckx de Casterle B, Frings-Dresen MHW, De Boer AGEM, Greidanus MA, Tamminga SJ, De Rijk AE. Employers' experience of employees with cancer: trajectories of complex communication. J Cancer Surviv. 2017 Oct;11(5):562-577. doi: 10.1007/s11764-017-0626-z. Epub 2017 Jul 14. PubMed 28710544 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Apr 2025 (actual). Primary completion is estimated for Dec 2026, 20 months after the start.

Primary completion moved once since we started tracking on Sep 25, 2026: Jun 2026 → Dec 2026, on Nov 20, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2025
First posted
May 29, 2025
StartActual
Apr 1, 2025
Primary completionEst.
Dec 2026was Jun 2026
CompletionEst.
Feb 2027
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jun 2026→Dec 2026
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Primary completion Jun 2026→Dec 2026
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06994182
Lead sponsor
Azienda USL Reggio Emilia - IRCCS
Collaborators
Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC)
Responsible party
Sponsor
First posted
May 29, 2025
Start date
Apr 1, 2025
Primary completion
Dec 2026 (estimated)
Completion
Feb 2027 (estimated)
Last update
Nov 20, 2026

Study contacts

Sara Paltrinieri, PhD, OT
Contact
sara.paltrinieri@ausl.re.it
0039 0522 522416
Stefania Costi, PhD, PT
Contact
stefania.costi@unimore.it
0039 0522 522441
Sara Paltrinieri, PhD, OT
principal investigator · Azienda USL Reggio Emilia - IRCCS

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion